Ionis Pharmaceuticals INC Form 4 insider transactions

Michael R Hayden, a Director of Ionis Pharmaceuticals Inc, purchased 20,000 shares of common stock on July 30, 2026.

Peter N Reikes, a Director of Ionis Pharmaceuticals Inc, received 3,399 shares of common stock on July 15, 2026.

Ludwig Hantson, a Director of Ionis Pharmaceuticals Inc, received 3,399 shares of common stock on July 15, 2026.

Joan E Herman, a Director of Ionis Pharmaceuticals Inc, reported multiple transactions in common stock on July 15, 2026.

Spencer R Berthelsen, a Director of Ionis Pharmaceuticals Inc, reported multiple transactions in common stock on July 15, 2026.

C. Frank Bennett, EVP and Chief Scientific Officer at Ionis Pharmaceuticals, reported transactions involving the sale of company stock and a transfer to a trust.

Allene M. Diaz, a Director at Ionis Pharmaceuticals Inc., has sold 10,111 shares of common stock, a transaction executed under a pre-arranged trading plan.

Holly B. Kordasiewicz, EVP and Chief Development Officer at Ionis Pharmaceuticals, sold 362 shares of common stock on July 7, 2026, valued at $84.3 per share, as part of a pre-established trading plan.

Michael J. Yang, a Director at Ionis Pharmaceuticals, reports on equity grants including stock options and restricted stock units.

Joseph Loscalzo, a Director at Ionis Pharmaceuticals, received stock options and restricted stock units on July 1, 2026, with specific vesting and exercise terms.

Joan E. Herman, a Director at Ionis Pharmaceuticals, reports the grant of stock options and restricted stock units with specific vesting conditions and a cap on annual equity compensation.

Ionis Pharmaceuticals Director Joseph Klein III reports transactions involving common stock, including sales under a 10b5-1 plan and new equity awards.

Michael R. Hayden, a Director at Ionis Pharmaceuticals, reports on the acquisition of stock options and restricted stock units.

Allene M. Diaz, a Director at Ionis Pharmaceuticals, received stock options and restricted stock units on July 1, 2026, with specific vesting and deferral terms.

Spencer R. Berthelsen, a Director at Ionis Pharmaceuticals, reports the grant of stock options and restricted stock units.

Joseph Baroldi, EVP and Chief Business Officer at Ionis Pharmaceuticals, reported transactions involving the acquisition and disposition of company stock.

Ionis Pharmaceuticals EVP and General Counsel Patrick R. O'Neil sold 3,069 shares of common stock on June 26, 2026, valued at approximately $80 per share, as part of a pre-arranged trading plan.

Eugene Schneider, EVP and Chief Clinical Development Officer at Ionis Pharmaceuticals, sold 26,000 shares of common stock.

Ionis Pharmaceuticals CEO Brett P. Monia executed a series of stock transactions, acquiring and selling common stock under a pre-arranged trading plan.

Ionis Pharmaceuticals EVP Eric Swayze reported a sale of 10,602 shares of common stock on June 25, 2026, executed under a Rule 10b5-1 trading plan.

EVP and Chief Development Officer Holly Kordasiewicz exercised stock options and sold 60,846 shares of Ionis Pharmaceuticals.

Ionis Pharmaceuticals Director Spencer R. Berthelsen exercised options and sold 8,000 shares of common stock under a 10b5-1 plan.

Director Peter N. Reikes was granted 10,753 non-qualified stock options in Ionis Pharmaceuticals, Inc. as part of the company's director compensation plan.

Director Ludwig Hantson was granted 10,753 stock options in Ionis Pharmaceuticals as part of the company's non-employee director compensation plan.

Ionis Pharmaceuticals Director Spencer R. Berthelsen exercised options and sold 8,000 shares of common stock.

Ionis Pharmaceuticals CEO Brett P. Monia exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Director Joseph Loscalzo exercised stock options and sold 77,289 shares under a Rule 10b5-1 trading plan.

Director Joseph Klein III reports stock transactions, including sales under a 10b5-1 plan and option exercises.

EVP and Chief Business Officer Joseph Baroldi sold 1,626 shares of Ionis Pharmaceuticals common stock via a 10b5-1 plan.

Ionis Pharmaceuticals Director B. Lynne Parshall sold 5,000 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.